NanoViricides, Inc.: A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum

Related Keywords

United States ,India ,Japan ,Japanese ,American ,Sulfated Proteoglycans ,Theracour Pharma Inc ,European Medicines Agency ,Drug Administration ,Committee For Medicinal Products Human ,Securities Exchange ,Virus Killing Technology Platform ,Exchange Commission ,Nanoviricides Inc ,Novel Host Mimetic ,Virus Killing Technology ,Mimetic Technology To Solve ,Greatest Pain ,Antiviral Medicines ,Broad Antiviral Spectrum ,Phasei Human Clinical Trials ,Executive Chairman ,Karveer Meditech ,Human Immunodeficiency Virus ,Hepatitisb Virus ,Hepatitisc Virus ,Herpes Simplex Virus ,Varicella Zoster Virus ,Asian Bird Flu Virus ,Japanese Encephalitis ,West Nile Virus ,Theracour Pharma ,Securities Act ,Securities Exchange Act ,United States Securities ,Good Manufacturing ,Medicinal Products ,Human Use ,Relations Contact ,Ihr Portfolio ,